Literature DB >> 30428975

Past-in-the-Future. Peak detection improves targeted mass spectrometry imaging.

Francesca Falcetta1, Lavinia Morosi1, Paolo Ubezio1, Silvia Giordano2, Alessandra Decio1, Raffaella Giavazzi1, Roberta Frapolli1, Mridula Prasad3, Pietro Franceschi4, Maurizio D'Incalci1, Enrico Davoli5.   

Abstract

Mass spectrometry imaging is a valuable tool for visualizing the localization of drugs in tissues, a critical issue especially in cancer pharmacology where treatment failure may depend on poor drug distribution within the tumours. Proper preprocessing procedures are mandatory to obtain quantitative data of drug distribution in tumours, even at low intensity, through reliable ion peak identification and integration. We propose a simple preprocessing and quantification pipeline. This pipeline was designed starting from classical peak integration methods, developed when "microcomputers" became available for chromatography, now applied to MSI. This pre-processing approach is based on a novel method using the fixed mass difference between the analyte and its 5 d derivatives to set up a mass range gate. We demonstrate the use of this pipeline for the evaluating the distribution of the anticancer drug paclitaxel in tumour sections. The procedure takes advantage of a simple peak analysis and allows to quantify the drug concentration in each pixel with a limit of detection below 0.1 pmol mm-2 or 10 μg g-1. Quantitative images of paclitaxel distribution in different tumour models were obtained and average paclitaxel concentrations were compared with HPLC measures in the same specimens, showing <20% difference. The scripts are developed in Python and available through GitHub, at github.com/FrancescaFalcetta/Imaging_of_drugs_distribution_and_quantifications.git.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Imaging data analysis; Mass spectrometry images; Preprocessing; Quantitative imaging; Tumour drug distribution

Mesh:

Substances:

Year:  2018        PMID: 30428975     DOI: 10.1016/j.aca.2018.06.067

Source DB:  PubMed          Journal:  Anal Chim Acta        ISSN: 0003-2670            Impact factor:   6.558


  3 in total

1.  Evaluation of the tumor-targeting efficiency and intratumor heterogeneity of anticancer drugs using quantitative mass spectrometry imaging.

Authors:  Jin Zhang; Qianqian Du; Xiaowei Song; Shanshan Gao; Xuechao Pang; Yan Li; Ruiping Zhang; Zeper Abliz; Jiuming He
Journal:  Theranostics       Date:  2020-02-03       Impact factor: 11.556

2.  Quantitative determination of niraparib and olaparib tumor distribution by mass spectrometry imaging.

Authors:  Lavinia Morosi; Cristina Matteo; Tommaso Ceruti; Silvia Giordano; Marianna Ponzo; Roberta Frapolli; Massimo Zucchetti; Enrico Davoli; Maurizio D'Incalci; Paolo Ubezio
Journal:  Int J Biol Sci       Date:  2020-02-21       Impact factor: 6.580

3.  PEGylated recombinant human hyaluronidase (PEGPH20) pre-treatment improves intra-tumour distribution and efficacy of paclitaxel in preclinical models.

Authors:  Lavinia Morosi; Marina Meroni; Maurizio D'Incalci; Roberta Frapolli; Paolo Ubezio; Ilaria Fuso Nerini; Lucia Minoli; Luca Porcu; Nicolò Panini; Marika Colombo; Barbara Blouw; David W Kang; Enrico Davoli; Massimo Zucchetti
Journal:  J Exp Clin Cancer Res       Date:  2021-09-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.